Cargando…
Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency
BACKGROUND: We studied whether endothelin receptor antagonist and calcimimetic treatments influence renal damage and kidney renin-angiotensin (RA) components in adenine-induced chronic renal insufficiency (CRI). METHODS: Male Wistar rats (n = 80) were divided into 5 groups for 12 weeks: control (n =...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659028/ https://www.ncbi.nlm.nih.gov/pubmed/29078759 http://dx.doi.org/10.1186/s12882-017-0742-z |
_version_ | 1783274102170058752 |
---|---|
author | Törmänen, Suvi Pörsti, Ilkka Lakkisto, Päivi Tikkanen, Ilkka Niemelä, Onni Paavonen, Timo Mustonen, Jukka Eräranta, Arttu |
author_facet | Törmänen, Suvi Pörsti, Ilkka Lakkisto, Päivi Tikkanen, Ilkka Niemelä, Onni Paavonen, Timo Mustonen, Jukka Eräranta, Arttu |
author_sort | Törmänen, Suvi |
collection | PubMed |
description | BACKGROUND: We studied whether endothelin receptor antagonist and calcimimetic treatments influence renal damage and kidney renin-angiotensin (RA) components in adenine-induced chronic renal insufficiency (CRI). METHODS: Male Wistar rats (n = 80) were divided into 5 groups for 12 weeks: control (n = 12), 0.3% adenine (Ade; n = 20), Ade + 50 mg/kg/day sitaxentan (n = 16), Ade + 20 mg/kg/day cinacalcet (n = 16), and Ade + sitaxentan + cinacalcet (n = 16). Blood pressure (BP) was measured using tail-cuff, kidney histology was examined, and RA components measured using RT-qPCR. RESULTS: Adenine caused tubulointerstitial damage with severe CRI, anemia, hyperphosphatemia, 1.8-fold increase in urinary calcium excretion, and 3.5-fold and 18-fold increases in plasma creatinine and PTH, respectively. Sitaxentan alleviated tubular atrophy, while sitaxentan + cinacalcet combination reduced interstitial inflammation, tubular dilatation and atrophy in adenine-rats. Adenine diet did not influence kidney angiotensin converting enzyme (ACE) and AT(4) receptor mRNA, but reduced mRNA of renin, AT(1a), AT(2), (pro)renin receptor and Mas to 40–60%, and suppressed ACE2 to 6% of that in controls. Sitaxentan reduced BP by 8 mmHg, creatinine, urea, and phosphate concentrations by 16–24%, and PTH by 42%. Cinacalcet did not influence BP or creatinine, but reduced PTH by 84%, and increased hemoglobin by 28% in adenine-rats. The treatments further reduced renin mRNA by 40%, while combined treatment normalized plasma PTH, urinary calcium, and increased ACE2 mRNA 2.5-fold versus the Ade group (p < 0.001). CONCLUSIONS: In adenine-induced interstitial nephritis, sitaxentan improved renal function and tubular atrophy. Sitaxentan and cinacalcet reduced kidney renin mRNA by 40%, while their combination alleviated tubulointerstitial damage and urinary calcium loss, and increased kidney tissue ACE2 mRNA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12882-017-0742-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5659028 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56590282017-11-01 Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency Törmänen, Suvi Pörsti, Ilkka Lakkisto, Päivi Tikkanen, Ilkka Niemelä, Onni Paavonen, Timo Mustonen, Jukka Eräranta, Arttu BMC Nephrol Research Article BACKGROUND: We studied whether endothelin receptor antagonist and calcimimetic treatments influence renal damage and kidney renin-angiotensin (RA) components in adenine-induced chronic renal insufficiency (CRI). METHODS: Male Wistar rats (n = 80) were divided into 5 groups for 12 weeks: control (n = 12), 0.3% adenine (Ade; n = 20), Ade + 50 mg/kg/day sitaxentan (n = 16), Ade + 20 mg/kg/day cinacalcet (n = 16), and Ade + sitaxentan + cinacalcet (n = 16). Blood pressure (BP) was measured using tail-cuff, kidney histology was examined, and RA components measured using RT-qPCR. RESULTS: Adenine caused tubulointerstitial damage with severe CRI, anemia, hyperphosphatemia, 1.8-fold increase in urinary calcium excretion, and 3.5-fold and 18-fold increases in plasma creatinine and PTH, respectively. Sitaxentan alleviated tubular atrophy, while sitaxentan + cinacalcet combination reduced interstitial inflammation, tubular dilatation and atrophy in adenine-rats. Adenine diet did not influence kidney angiotensin converting enzyme (ACE) and AT(4) receptor mRNA, but reduced mRNA of renin, AT(1a), AT(2), (pro)renin receptor and Mas to 40–60%, and suppressed ACE2 to 6% of that in controls. Sitaxentan reduced BP by 8 mmHg, creatinine, urea, and phosphate concentrations by 16–24%, and PTH by 42%. Cinacalcet did not influence BP or creatinine, but reduced PTH by 84%, and increased hemoglobin by 28% in adenine-rats. The treatments further reduced renin mRNA by 40%, while combined treatment normalized plasma PTH, urinary calcium, and increased ACE2 mRNA 2.5-fold versus the Ade group (p < 0.001). CONCLUSIONS: In adenine-induced interstitial nephritis, sitaxentan improved renal function and tubular atrophy. Sitaxentan and cinacalcet reduced kidney renin mRNA by 40%, while their combination alleviated tubulointerstitial damage and urinary calcium loss, and increased kidney tissue ACE2 mRNA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12882-017-0742-z) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-27 /pmc/articles/PMC5659028/ /pubmed/29078759 http://dx.doi.org/10.1186/s12882-017-0742-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Törmänen, Suvi Pörsti, Ilkka Lakkisto, Päivi Tikkanen, Ilkka Niemelä, Onni Paavonen, Timo Mustonen, Jukka Eräranta, Arttu Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency |
title | Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency |
title_full | Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency |
title_fullStr | Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency |
title_full_unstemmed | Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency |
title_short | Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency |
title_sort | endothelin a receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659028/ https://www.ncbi.nlm.nih.gov/pubmed/29078759 http://dx.doi.org/10.1186/s12882-017-0742-z |
work_keys_str_mv | AT tormanensuvi endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency AT porstiilkka endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency AT lakkistopaivi endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency AT tikkanenilkka endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency AT niemelaonni endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency AT paavonentimo endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency AT mustonenjukka endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency AT erarantaarttu endothelinareceptorblockerandcalcimimeticintheadenineratmodelofchronicrenalinsufficiency |